Symbols / OKYO
OKYO Chart
About
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase II clinical trials for the treatment of dry eye disease; in Phase II clinical trial to treat neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis. The company is also developing OK-201 for the treatment acute and chronic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 85.79M |
| Enterprise Value | 60.18M | Income | -4.61M | Sales | — |
| Book/sh | -0.09 | Cash/sh | 0.11 | Dividend Yield | — |
| Payout | 0.00% | Employees | 4 | IPO | — |
| P/E | — | Forward P/E | -8.35 | PEG | — |
| P/S | — | P/B | -18.76 | P/C | — |
| EV/EBITDA | -9.62 | EV/Sales | — | Quick Ratio | 0.53 |
| Current Ratio | 0.58 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -0.11 | EPS next Y | -0.20 | EPS Growth | — |
| Revenue Growth | — | Earnings | — | ROA | -104.63% |
| ROE | — | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 51.37M |
| Shs Float | 23.47M | Short Float | 1.02% | Short Ratio | 0.93 |
| Short Interest | — | 52W High | 3.35 | 52W Low | 1.03 |
| Beta | -0.23 | Avg Volume | 253.70K | Volume | 541.83K |
| Target Price | $8.00 | Recom | Strong_buy | Prev Close | $1.70 |
| Price | $1.67 | Change | -1.76% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$8.00
Mean price target
2. Current target
$1.67
Latest analyst target
3. DCF / Fair value
$-1.05
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.67
Low
$5.00
High
$13.00
Mean
$8.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-20 | init | Piper Sandler | — → Overweight | $7 |
| 2025-12-08 | init | B. Riley Securities | — → Buy | $5 |
| 2025-09-23 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2025-05-05 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2025-02-18 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2025-02-14 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2025-02-10 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-10-24 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-10-16 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-08-27 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-07-12 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-07-11 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-03-22 | main | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-01-08 | main | HC Wainwright & Co. | Buy → Buy | $5 |
| 2023-12-05 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2023-11-02 | init | HC Wainwright & Co. | — → Buy | $4 |
- Experimental eye drop eases nerve-related eye pain in first human study - Stock Titan Mon, 23 Feb 2026 16
- OKYO Pharma's Urcosimod Selected for Presentation at ARVO 2026 Annual Meeting Following Positive Phase 2a Trial Results for Neuropathic Corneal Pain Treatment - Quiver Quantitative Mon, 23 Feb 2026 16
- Piper Sandler initiates OKYO Pharma stock with Overweight rating - Investing.com Fri, 20 Feb 2026 13
- OKYO Pharma’s Urcosimod NCP Data Selected for Presentation at ARVO 2026 - TipRanks Mon, 23 Feb 2026 16
- OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares - Yahoo Finance hu, 12 Feb 2026 08
- H.C. Wainwright reiterates Buy rating on OKYO Pharma stock with $7 price target - Investing.com hu, 29 Jan 2026 08
- New Analyst Forecast: $OKYO Given $7 Price Target - Quiver Quantitative Fri, 20 Feb 2026 10
- OKYO Pharma taps Leerink to raise cash for eye pain treatments - Stock Titan Wed, 11 Feb 2026 08
- OKYO Pharma Announces Chairman and Founder Acquires Shares - Yahoo Finance Mon, 15 Dec 2025 08
- Doctor behind $1B rare-disease eye drug joins OKYO Pharma - Stock Titan ue, 10 Feb 2026 08
- OKYO Pharma Limited Transitions ATM Equity Offering to Leerink Partners LLC for Enhanced Capital Access - Quiver Quantitative Wed, 11 Feb 2026 08
- OKYO Pharma stock tumbles on $20 million public offering announcement - Investing.com South Africa Fri, 13 Feb 2026 14
- OKYO Pharma stock rises after FDA confirms Phase 2b/3 trial design - Investing.com Wed, 28 Jan 2026 08
- B.Riley initiates coverage on OKYO Pharma stock with Buy rating - Investing.com Mon, 08 Dec 2025 08
- OKYO Pharma Launches $50 Million At-the-Market Share Offering With Leerink Partners - TipRanks Wed, 11 Feb 2026 08
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.25 | 0.25 | 0.00 | 0.13 |
| NormalizedEBITDA | -7.10M | -15.75M | -13.18M | -6.22M |
| TotalUnusualItems | 0.00 | 0.00 | -11.17K | |
| TotalUnusualItemsExcludingGoodwill | 0.00 | 0.00 | -11.17K | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -4.71M | -16.83M | -13.27M | -5.43M |
| ReconciledDepreciation | 2.56K | 3.87K | 3.80K | 2.33K |
| EBITDA | -7.10M | -15.75M | -13.18M | -6.22M |
| EBIT | -7.10M | -15.75M | -13.19M | -6.22M |
| NetInterestIncome | -878.17K | -1.05M | -96.69K | 0.00 |
| InterestExpense | 870.28K | 1.05M | 96.69K | 0.00 |
| InterestIncome | 5.47K | 0.00 | 0.00 | 0.00 |
| NormalizedIncome | -4.71M | -16.83M | -13.27M | -5.43M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -4.71M | -16.83M | -13.27M | -5.43M |
| TotalExpenses | 7.09M | 15.75M | 13.19M | 6.22M |
| TotalOperatingIncomeAsReported | -4.13M | |||
| DilutedAverageShares | 39.49M | 29.34M | 22.26M | 798.26M |
| BasicAverageShares | 39.49M | 29.34M | 22.26M | 15.06M |
| DilutedEPS | -0.12 | -0.57 | -0.61 | -0.36 |
| BasicEPS | -0.12 | -0.57 | -0.61 | -0.36 |
| DilutedNIAvailtoComStockholders | -4.71M | -16.83M | -13.27M | -5.43M |
| NetIncomeCommonStockholders | -4.71M | -16.83M | -13.27M | -5.43M |
| OtherunderPreferredStockDividend | 0.00 | |||
| NetIncome | -4.71M | -16.83M | -13.27M | -5.43M |
| NetIncomeIncludingNoncontrollingInterests | -4.71M | -16.83M | -13.27M | -5.43M |
| NetIncomeContinuousOperations | -4.71M | -16.83M | -13.27M | -5.43M |
| TaxProvision | -3.26M | 22.42K | -12.20K | -786.52K |
| PretaxIncome | -7.97M | -16.80M | -13.28M | -6.22M |
| OtherIncomeExpense | -11.17K | |||
| SpecialIncomeCharges | 0.00 | 0.00 | -11.17K | |
| WriteOff | 0.00 | 0.00 | 11.17K | |
| ImpairmentOfCapitalAssets | 11.74K | |||
| NetNonOperatingInterestIncomeExpense | -878.17K | -1.05M | -96.69K | 0.00 |
| TotalOtherFinanceCost | 13.37K | |||
| InterestExpenseNonOperating | 870.28K | 1.05M | 96.69K | 0.00 |
| InterestIncomeNonOperating | 5.47K | 0.00 | 0.00 | 0.00 |
| OperatingIncome | -7.09M | -15.75M | -13.19M | -6.22M |
| OperatingExpense | 7.09M | 15.75M | 13.19M | 6.22M |
| OtherOperatingExpenses | 4.84M | 7.51M | 6.85M | 4.61M |
| ResearchAndDevelopment | 2.25M | 8.24M | 6.34M | 1.61M |
| SellingGeneralAndAdministration | 1.22M | |||
| GeneralAndAdministrativeExpense | 1.22M | |||
| SalariesAndWages | 1.22M | |||
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 36.02M | 33.34M | 51.04M | 21.14M |
| ShareIssued | 36.02M | 33.34M | 51.04M | 21.14M |
| TotalDebt | 2.22M | 0.00 | 98.76K | |
| TangibleBookValue | -5.55M | -5.88M | -2.05M | 2.95M |
| InvestedCapital | -5.55M | -5.88M | 161.87K | 2.95M |
| WorkingCapital | -5.55M | -5.88M | -2.06M | 2.94M |
| NetTangibleAssets | -5.55M | -5.88M | -2.05M | 2.95M |
| CapitalLeaseObligations | 0.00 | 98.76K | ||
| CommonStockEquity | -5.55M | -5.88M | -2.05M | 2.95M |
| TotalCapitalization | -5.55M | -5.88M | -2.05M | 2.95M |
| TotalEquityGrossMinorityInterest | -5.55M | -5.88M | -2.05M | 2.95M |
| StockholdersEquity | -5.55M | -5.88M | -2.05M | 2.95M |
| OtherEquityInterest | 2.23M | 4.84M | 3.71M | 2.41M |
| GainsLossesNotAffectingRetainedEarnings | -11.47M | -11.31M | -11.45M | -11.01M |
| ForeignCurrencyTranslationAdjustments | -11.47M | -11.31M | -11.45M | -11.01M |
| RetainedEarnings | -143.02M | -142.52M | -125.70M | -112.43M |
| AdditionalPaidInCapital | 67.15M | |||
| CapitalStock | 146.72M | 143.11M | 131.39M | 123.98M |
| CommonStock | 146.72M | 143.11M | 131.39M | 123.98M |
| TotalLiabilitiesNetMinorityInterest | 9.23M | 7.42M | 7.26M | 1.35M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 0.00 | 0.00 | 0.00 |
| LongTermDebtAndCapitalLeaseObligation | 0.00 | 64.61K | ||
| LongTermCapitalLeaseObligation | 0.00 | 64.61K | ||
| CurrentLiabilities | 9.23M | 7.42M | 7.26M | 1.35M |
| CurrentDebtAndCapitalLeaseObligation | 2.22M | 34.15K | ||
| CurrentCapitalLeaseObligation | 0.00 | 34.15K | ||
| CurrentDebt | 2.22M | |||
| OtherCurrentBorrowings | 2.22M | |||
| PayablesAndAccruedExpenses | 9.23M | 7.42M | 5.04M | 1.35M |
| CurrentAccruedExpenses | 378.58K | 830.17K | 1.88M | 564.34K |
| Payables | 8.85M | 6.59M | 3.17M | 788.85K |
| OtherPayable | 89.00K | 103.83K | 73.20K | |
| DuetoRelatedPartiesCurrent | 859.33K | 358.71K | 779.19K | 47.04K |
| AccountsPayable | 7.90M | 6.13M | 2.31M | 741.81K |
| TotalAssets | 3.68M | 1.54M | 5.20M | 4.30M |
| TotalNonCurrentAssets | 2.04K | 3.35K | 7.22K | 5.22K |
| NetPPE | 2.04K | 3.35K | 7.22K | 5.22K |
| AccumulatedDepreciation | -8.46K | -7.12K | -8.10K | -4.55K |
| GrossPPE | 10.50K | 10.47K | 15.31K | 9.78K |
| Leases | 98.17K | |||
| MachineryFurnitureEquipment | 10.50K | 10.47K | 15.31K | 9.78K |
| BuildingsAndImprovements | 71.42K | |||
| Properties | 0.00 | 98.58K | ||
| CurrentAssets | 3.68M | 1.54M | 5.20M | 4.30M |
| OtherCurrentAssets | 1.00 | |||
| PrepaidAssets | 225.36K | 130.13K | 171.25K | 711.21K |
| Receivables | 1.89M | 580.94K | 980.08K | 883.43K |
| OtherReceivables | 4.50K | 5.58K | 340.85K | 19.13K |
| DuefromRelatedPartiesCurrent | 0.00 | 27.66K | ||
| TaxesReceivable | 1.88M | 575.36K | 639.23K | 864.30K |
| CashCashEquivalentsAndShortTermInvestments | 1.56M | 826.85K | 4.05M | 2.70M |
| CashAndCashEquivalents | 1.56M | 826.85K | 4.05M | 2.70M |
| CashFinancial | 1.56M | 826.85K | 4.05M | 2.70M |
| Line Item | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| FreeCashFlow | -1.81M | -9.49M | -7.70M | -5.47M |
| RepaymentOfDebt | 0.00 | 0.00 | -12.33K | |
| IssuanceOfDebt | 950.00K | 0.00 | 2.00M | 0.00 |
| IssuanceOfCapitalStock | 1.71M | 6.21M | 7.32M | 0.00 |
| CapitalExpenditure | -1.21K | -5.92K | -1.67K | -6.94K |
| EndCashPosition | 1.56M | 826.85K | 4.05M | 2.70M |
| BeginningCashPosition | 826.85K | 4.05M | 2.70M | 6.89M |
| EffectOfExchangeRateChanges | -109.55K | 63.50K | -277.54K | -872.14K |
| ChangesInCash | 843.60K | -3.28M | 1.62M | -3.32M |
| FinancingCashFlow | 2.66M | 6.21M | 9.32M | 2.15M |
| CashFlowFromContinuingFinancingActivities | 2.66M | 6.21M | 9.32M | 2.15M |
| NetOtherFinancingCharges | 1.18K | |||
| ProceedsFromStockOptionExercised | 0.00 | 0.00 | 2.15M | 15.87K |
| NetCommonStockIssuance | 1.71M | 6.21M | 7.32M | 0.00 |
| CommonStockIssuance | 1.71M | 6.21M | 7.32M | 0.00 |
| NetIssuancePaymentsOfDebt | 950.00K | 0.00 | 2.00M | 0.00 |
| NetShortTermDebtIssuance | 950.00K | 0.00 | 2.00M | 0.00 |
| ShortTermDebtIssuance | 950.00K | 0.00 | 2.00M | 0.00 |
| NetLongTermDebtIssuance | 0.00 | 0.00 | 0.00 | -12.33K |
| LongTermDebtPayments | 0.00 | 0.00 | -12.33K | |
| LongTermDebtIssuance | 0.00 | 0.00 | 0.00 | 7.59M |
| InvestingCashFlow | -1.21K | 0.00 | -5.92K | -1.67K |
| CashFlowFromContinuingInvestingActivities | -1.21K | 0.00 | -5.92K | -1.67K |
| NetOtherInvestingChanges | -11.17K | |||
| NetPPEPurchaseAndSale | -1.21K | 0.00 | -5.92K | -1.67K |
| PurchaseOfPPE | -1.21K | 0.00 | -5.92K | -1.67K |
| OperatingCashFlow | -1.81M | -9.49M | -7.70M | -5.47M |
| CashFlowFromContinuingOperatingActivities | -1.81M | -9.49M | -7.70M | -5.47M |
| TaxesRefundPaid | 2.00M | 0.00 | 199.15K | 0.00 |
| ChangeInWorkingCapital | 1.63M | 2.67M | 3.95M | -1.02M |
| ChangeInOtherCurrentAssets | -90.40K | 440.26K | 167.72K | -802.15K |
| ChangeInPayablesAndAccruedExpense | 1.72M | 2.23M | 3.78M | -249.09K |
| ChangeInPayable | 1.72M | 2.23M | 3.78M | -249.09K |
| ChangeInAccountPayable | 1.22M | 2.80M | 2.96M | -297.99K |
| ChangeInReceivables | 0.00 | 167.72K | 27.38K | 205.07K |
| ChangesInAccountReceivables | 27.38K | -2.81K | ||
| OtherNonCashItems | 1.99M | 3.46M | 114.99K | 61.72K |
| StockBasedCompensation | 734.99K | 1.12M | 1.29M | 1.74M |
| AssetImpairmentCharge | 0.00 | 0.00 | 11.17K | |
| DepreciationAmortizationDepletion | 2.56K | 3.87K | 3.80K | 2.33K |
| DepreciationAndAmortization | 2.56K | 3.87K | 3.80K | 2.33K |
| Depreciation | 2.56K | 3.87K | 3.80K | 2.33K |
| OperatingGainsLosses | -191.26K | 53.76K | 38.78K | -28.56K |
| GainLossOnInvestmentSecurities | -94.28K | -1.42K | -12.41K | -19.15K |
| NetForeignCurrencyExchangeGainLoss | -96.98K | 55.18K | 51.19K | -9.23K |
| GainLossOnSaleOfPPE | 0.00 | 0.00 | -179.00 | -818.00 |
| NetIncomeFromContinuingOperations | -7.97M | -16.80M | -13.28M | -6.22M |
Public Trades for OKYO
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|